度洛西汀治疗持续性躯体形式疼痛障碍的临床研究  

Clinical study of duloxetine in treatment of persistent somatoform pain disorder

作　　者：任婉文[1] 张颖[1] 龙森[2] 毛洪京[1] 陈树林[3] 

机构地区：[1]杭州市第七人民医院医学心理科 [2]杭州市第七人民医院药剂科 [3]浙江大学心理系

出　　处：《中国临床药理学与治疗学》2015年第11期1287-1292,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：杭州市科技发展计划医学重点专病专科专项(20091233Q16);杭州市卫生局项目基金(2009B024)

摘　　要：目的:探讨度洛西汀对持续性躯体形式疼痛障碍患者的疗效和安全性。方法:采用随机双盲安慰剂对照试验设计和跟踪随访研究,选择70例持续性躯体形式疼痛障碍患者,随机分配到试验组(口服度洛西汀片)和对照组(口服安慰剂),分别于治疗前、治疗后第1,2,4和6周末采用简易McGill疼痛量表(SF-MPQ)、汉密尔顿抑郁量表(HAMD;17项)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和副反应;并对试验组治疗6周末SF-MPQ疼痛分级指数(PRI)总分减分率≥50%者进入随访研究。结果:治疗1周后两组患者的SF-MPQ、HAMD、HAMA各项评分较治疗前均有不同程度的降低,差异均有统计学意义(P<0.05),治疗后第1周末现有疼痛强度PPI,第2周、4周和6周末SF-MPQ、HAMD、HAMA各项评分试验组较对照组均降低,差异均有统计学意义(P<0.05)。试验组不良反应总例次较对照组高(P<0.05),但单个不良反应发生率之间差异无统计学意义。试验组共有17例患者PRI总分减分率≥50%者进入随访研究,随访3个月和6个月与治疗6周末各项评分变化相近差异均无统计学意义(P>0.05)。结论:度洛西汀对治疗持续性躯体形式疼痛障碍患者有较好的临床疗效,安全性高。AIM：To explore the therapeutic effect and safety of duloxetine in treating patients with persistent somatoform pain disorder（PSPD）.METHODS：A randomized,double-blind,placebo-controlled and follow-up study were taken.70 PSPD patients were involved in our study,randomly divided into 2 groups separately using the duloxetine and the placebo.The patients were evaluated with simplified mcGill score chart for paining（SFMPQ）,hamilton depression scale（HAMD）,hamilton anxiety scale（HAMA） and treatment emergent symptom scale（TESS） before and after treatment,（1,2,4 and 6weeks）,respectively.Those patients with the reducing score rate of SF-MPQ in present rating index（PRI）≥50%were involved in the follow-up study and evaluated with SF-MPQ,HAMD,HAMA and TESS after 3,6 months.RESULTS：All the scores of SF-VIPQ,HAMD and HAMA 1week after treatment in both groups were significantly different with those scores before treatment（P〈0.05）.The scores of present pain intensity（PPI）after one week treatment,and the scores of SFMPQ,HAMD and HAMA after 2,4 and 6 weeks of the treatment were significantly different between the two groups（P〈0.05）.The total side effects in treatment group were higher than that in the control group（P〈0.05）.However,there was no significant difference in the incidence of single side effects.There were 17 patients with the reducing score rate of PRI-50%who were involved in the follow-up study.Comparing to 6 weeks after treatment,no significant difference were observed at 3and 6months after treatment（P〉0.05）.CONCLUSION：Duloxetine is effective and safety treatment of patient with persistent somatoform pain disorder.

关 键 词：度洛西汀 持续性躯体形式疼痛障碍 随机双盲设计 

分 类 号：R741[医药卫生—神经病学与精神病学]